Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Augmenix closes $10.8mm Series D

Executive Summary

Augmenix Inc. raised $10.8mm through its Series D round. New buyers Excelestar Ventures and unnamed individuals participated, along with returning investors CHV II, Catalyst Health Ventures, and Sparta Group. Funds will support FDA approval and market launch of SpaceOAR, a minimally invasive absorbable hydrogel that acts as a spacer to push the rectum out of the radiation field during prostate radiotherapy.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies